Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life

Journal of Clinical Investigation

Volumn 109, Issue 1, 2002, Pages 101-110

  Nagashima, Mariko ^a   Yin, Zheng Feng ^b   Zhao, Lei ^a   White, Kathy ^a   Zhu, Yanhong ^c   Lasky, Nina ^b   Halks Miller, Meredith ^a   Broze Jr , George J ^b   Fay, William P ^c   Morser, John ^a  

^a BAYER AG   (Germany)

^b BARNES JEWISH HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANIMAL CELL; ARTICLE; DISSEMINATED INTRAVASCULAR CLOTTING; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ENZYME DEFICIENCY; EXTRACELLULAR MATRIX; FIBRINOLYSIS; GENE DISRUPTION; GENE TARGETING; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; THROMBOSIS;

EID: 0036143120     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0212119     Document Type: Article

References (65)

1. The plasminogen activator/plasminogen system
2. The intrinsic lysis concept
3. Fibrinolysis and the control of hemostasis
4. The fibrinolytic system: From Petri dishes to genetic engineering
5. The plasma carboxypeptidases and the regulation of the plasminogen system
6. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N
7. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits
8. Isolation, molecular cloning and partial characterization of a novel carboxypeptidase B from human plasma
9. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
10. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor
11. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascade through the thrombin-thrombomodulin complex
12. Activation and characterization of procarboxypeptidase B from human plasma
13. Plasma carboxypeptidases as regulators of the plasminogen system
14. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
15. Thrombin-mediated activation of factor XI results in a TAFI-dependent inhibition of fibrinolysis
16. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma carboxypeptidase B
17. Pro-carboxypeptidase R cleaves bradykinin following activation
18. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis
19. Identification of the domains of tissue-type plasminogen activator involved in the augmented binding of fibrin after limited digestion with plasmin
20. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin
21. The mechanism of plasminogen activation and variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis
22. Thrombin-activatable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator
23. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI
24. A novel approach to arterial thrombolysis
25. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model
26. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis
27. Carboxypeptidase U and inhibitors increase the rate of fibrinolysis in a rat DIC model
28. TAFIA inhibitors enhance fibrinolysis in tissue factor-induced rat DIC model
29. Structure and function of mammalian zinc carboxypeptidases
30. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis
31. Physiological consequences of loss of plasminogen activator gene function in mice
32. Plasminogen deficiency causes severe thrombosis but compatible with development and reproduction
33. Impaired wound healing in mice with a disrupted plasminogen gene
34. α2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding
35. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity
36. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma
37. Tissue factor inhibitor (TFPI) gene-disruption produces embryonic lethality in mice
38. Optimized microturbidometric assay for fibrinogen
39. Hyperlipidemia promotes thrombosis after injury to atherosclerosis vessels in apolipoprotein E-deficient mice
40. Kaolin-induced writhing in mice, a new model of possible bradykinin-induced pain for assessment of analgesic agents
41. Evidence for a role of bradykinin in experimental pain models
42. Characterization of mouse thrombin-activable fibrinolysis inhibitor
43. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not
44. A tail vein bleeding time model and delayed bleeding in hemophiliac mice
45. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator
46. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
47. Assay of procarboxypeptidase U, a novel determination of the fibrinolytic cascade, in human
48. Plasma TAFI antigen variations in healthy subjects
49. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
50. Identification and characterization of two Thrombin-activatable fibrinolysis inhibitor isoforms
51. Characterization of the gene encoding human TAFI (Thrombin-activatable fibrinolysis inhibitor; plasma procarboxypeptidase B)
52. A polymorphism at position -438 in the promoter region of thrombin-activatable fibrinolysis inhibitor is strongly associated with plasma antigen level in healthy older men and women
53. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled
54. The gene encoding human plasma carboxypeptidase B resides on chromosome 13
55. The gene for human carboxypeptidase U maps to 13q14.11
56. Evaluation of TAFI plasma antigen and genotypes in myocardial infarction patients and controls from the North and South Europe (HIFMECH:Study)
57. Plasminogen activator-1 and vitronectin promote vascular thrombosis in mice
58. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury
59. Antithrombotic effect of recombinant thrombomodulin on thrombin-induced thromboembolism in mice
60. Antithrombotic effects of recombinant soluble human thrombomodulin analogs in animal models of tissue-factor and thrombin induced DIC
61. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation
62. Disseminated intravascular coagulation
63. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response of endotoxin?
64. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of αantiplasmin and PAI-1
65. Generation and characterization of thrombin activatable fibrinolysis inhibitor deficient mice